Supplementary Table 1. Trial registration dataset in accordance with World Health Organization (WHO)

Data category	Information[32]
Primary registry and trial identifying number	ClinicalTrials.gov Identifier: NCT03941587
Date of registration in primary registry	24/11/2020
Secondary identifying numbers	Singhealth CIRB Ref No. 2020/2857 SERI Ref. No. R1735/58/2020
Source(s) of monetary or material support	National Medical Research Council Singapore Open Fund Large Collaborative Grant (NMRCLCG17MAY013)
Primary sponsor	Singapore Eye Research Institute, Singapore National Eye Centre
Secondary sponsor(s)	Singapore Eye Research Institute, Singapore National Eye Centre
Contact for public queries	Gemmy Chui Ming Cheung, FRCO*phth* Email: gemmy.cheung.c.m@singhealth.com.sg
Contact for scientific queries	Gemmy Chui Ming Cheung, FRCO*phth* Email: gemmy.cheung.c.m@singhealth.com.sg
Public title	Comparing intravitreal Aflibercept monotherapy vs Aflibercept combined with RF-PDT in PCV treatment
Scientific title	A multi-centre, randomized clinical trial comparing intravitreal aflibercept monotherapy vs aflibercept combined with reduced fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
Countries of recruitment	Singapore
Health condition(s) or problem(s) studied	Polypoidal Choroidal Vasculopathy
Intervention(s)	Aflibercept 2mg intravitreal injection (IVA) Monotherapy group
	Aflibercept 2mg intravitreal injection combined with RF-PDT Combination group
Key inclusion and exclusion criteria	Ages eligible for study: ≥50 years Sexes eligible for study: both Accepts healthy volunteers: no
	Inclusion criteria: Treatment naïve eyes diagnosed with ICGA proven polypoidal choroidal vasculopathy; Best corrected logMAR visual acuity score between 73 to 4 letters (ie 20/32 to 20/320)
	Exclusion criteria: Known allergy to any component of the study drug. Any other ocular condition other than PCV.
Study type	Interventional
	Multi-centre Randomised, triple masked, open label, two arm, , phase 4 investigator-initiated clinical trial.
	Primary purpose: treatment
	Phase IV
Date of first enrolment	11 January 2021
Target sample size	160 subjects
Recruitment status	Recruitment started
Primary outcome(s)	compare the change in BCVA from baseline to week 52 between the combination group (IVA + RF-PDT) and the IVA monotherapy group.
Key secondary outcomes	Anatomical outcomes at week 12 and 52 between treatment groups (assessed by multimodal imaging) and Retreatment number between treatment groups

Supplementary Table 2. Polypoidal Choroidal Vasculopathy Grading Sheet (*per study visit*)

GRADING SHEET									
PDT_PCV	**DEMOGRAPHICS**				**HISTORY**				
STUDY ID	Age (yrs)	Race (Chinese/Malay/Indian)	Sex (male/female)	Laterality (right/left)	Smoking (yes/no)	HPN (yes/no)	IHD (yes/no)	DM (yes/no)	BCVA (yes/no)
PDT(SNEC)001									

PDT_PCV	**FUNDUS COLORED PHOTOS**							
STUDY ID	presence of Subretinal orange nodule (yes/no)	Presence of sub-retinal haemorrhage (yes/no)	Total lesion area (mm^2)	area of haemorrhage (mm^2)	presence of drusen (yes/no)	Soft drusen (yes/no)	Pachydrusen (yes/no)	Pseudodrusen (yes/no)
PDT(SNEC)001								

PDT_PCV	**ICGA**						**FA**			
STUDY ID **PDT_PCV**	Presence of Pachyvessels (yes/no)	choroidal vascular hyperpermeability (yes/no)	polypoidal lesions (yes/no)	branching network (yes/no)	branching network area (mm^2)	polypoidal lesions area (mm^2)	Leakage (yes/no)	Type (classic/occult)	polypoidal lesion leakage (yes/no)	BVN leakage (yes/no)
PDT(SNEC)001										

PDT_PCV	**SD - OCT**									
STUDY ID **PDT_PCV**	subretinal fluid (yes/no)	Intraretinal fluid (yes/no)	Hyper-reflective foci (yes/no)	sub-retinal hyper reflective material (yes/no)	PED > 100µm (yes/no)	Serous PED (yes/no)	Fibro-vascular PED (yes/no)	Haemorrhagic PED (yes/no)	Maximum PED width (um)	Maximum PED height (um)
PDT(SNEC)001										

PDT_PCV	**SD – OCT (continuation)**								
STUDY ID **PDT_PCV**	Foveal PED involvement (yes/no)	Double Layer (yes/no)	Notch PED (yes/no)	Sharp peaked PED (yes/no)	Sub-RPE ring lesion (yes/no)	height of ring lesion (um)	height of PED (um)	Sub foveal choroidal thickness (um)	Attenuation of choriocapillaris (yes/no)
PDT(SNEC)001									